HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) (BSE: 500124) (NSE: DRREDDY) today announced its consolidated financial results for the quarter ended September 30, 2015 under International Financial Reporting Standards (IFRS).
Q2 FY16: Key Highlights
•Consolidated revenues at Rs. 39.9 billion, year-on-year growth of 11%. In constant currency terms the revenue growth is 14%
Help employers find you! Check out all the jobs and post your resume.
